Posted by Kate Murphy on December 15th, 2008
The Food and Drug Administration is reporting shortages of leucovorin calcium, used to enhance the effectiveness of 5-FU (fluorouracil) in treating colorectal cancer. The reason the FDA gives for the shortage is “Manufacturing Delays.” Leucovorin is supplied by Teva Pharmaceuticals and Bedford Laboratories, and the FDA directs consumers to contact them for more information.
According to a bulletin from the American Society of Health System Pharmacists (ASHP), “Leucovorin calcium lyophilized powder is on back order and the company cannot estimate a release date.” In addition, ASHP has been told, “The manufacturers will not provide a reason for the shortage.” ASHP updated their information with personal communications with the manufacturers on December 8, 2008.
Calls from to the FDA, Teva, and Bedford from patient advocates on December 12 provided no new information about what was causing the problem or when it might be resolved.
The shortage not only affects thousands of colon and rectal cancer patients who are being treated with 5-FU and leucovorin, it impacts over one hundred clinical trials in the United States where leucovorin is part of treatment protocols. Read the rest of this entry »